| Literature DB >> 23420611 |
Kelly A Hirko1, Amr S Soliman, Mousumi Banerjee, Julie Ruterbusch, Joe B Harford, Robert M Chamberlain, John J Graff, Sofia D Merajver, Kendra Schwartz.
Abstract
INTRODUCTION: Inflammatory breast cancer (IBC) is characterized by an apparent geographical distribution in incidence, being more common in North Africa than other parts of the world. Despite the rapid growth of immigrants to the United States from Arab nations, little is known about disease patterns among Arab Americans because a racial category is rarely considered for this group. The aim of this study was to advance our understanding of the burden of IBC in Arab ethnic populations by describing the proportion of IBC among different racial groups, including Arab Americans from the Detroit, New Jersey and California Surveillance, Epidemiology and End Results (SEER) registries.Entities:
Keywords: Arab; Hierarchical logistic regression; Inflammatory breast cancer; Race
Year: 2013 PMID: 23420611 PMCID: PMC3568481 DOI: 10.1186/2193-1801-2-3
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Inflammatory breast cancer characteristics by race
| Arab | NHWa | NHBb | Hispanic | Asian | AI_Alc | p-value | ||
|---|---|---|---|---|---|---|---|---|
| (n=94) | (n=6,035) | (n=1,085) | (n=1,415) | (n=449) | (n=19) | |||
| n (%) | n(%) | n(%) | n(%) | n(%) | n(%) | |||
| Positive | 38 (42.2%) | 2,219 (39.3%) | 332 (32.1%) | 491 (36.4%) | 156 (36.7%) | 7 (36.8%) | ||
| Negative | 36 (40.0%) | 1,833 (32.4%) | 391 (37.7%) | 474 (35.1%) | 156 (36.7%) | 7 (36.8%) | ||
| Unknown | 16 (17.8%) | 1,598 (28.3) | 313 (30.2%) | 384 (28.5%) | 113 (26.6%) | 5 (26.3%) | ||
| Positive | 23 (25.6%) | 1,762 (31.2%) | 252 (24.3%) | 380 (28.2%) | 117 (27.5%) | 4 (21.1%) | ||
| Negative | 50 (55.5%) | 2,195 (38.8%) | 453 (43.7%) | 570 (42.2%) | 189 (44.5%) | 10 (52.6%) | ||
| Unknown | 17 (18.9%) | 1,693 (30%) | 331 (32%) | 399 (29.6%) | 119 (28%) | 5 (26.3%) | ||
| ER+ PR+ | 20 (27.4%) | 1,597 (40.6%) | 222 (31.6%) | 336 (35.7%) | 108 (35.3%) | 4 (28.6%) | ||
| ER+ PR- | 17 (23.3%) | 538 (13.7%) | 98 (14%) | 136 (14.4%) | 44 (14.4%) | 3 (21.4%) | 0.0948 | |
| ER- PR+ | 3 (4.1%) | 158 (4.0%) | 28 (4%) | 42 (4.5%) | 9 (2.9%) | 0 (0%) | 0.8900 | |
| ER- PR - | 33 (45.2%) | 1,642 (41.7%) | 354 (50.4%) | 428 (45.4%) | 145 (47.4%) | 7 (50.0%) | ||
| Positive | 14 (29.2%) | 594 (21.9%) | 94 (17.9%) | 248 (29.9%) | 83 (31.1%) | 2(18.2%) | ||
| Negative | 12 (25.0%) | 906 (33.4%) | 166 (31.7%) | 310 (37.3%) | 91 (34.1%) | 5 (45.5%) | ||
| Unknown | 22 (45.8%) | 1,209 (44.6%) | 264 (50.4%) | 272 (32.8%) | 93 (34.8%) | 4 (36.3%) | ||
| High | 36 (38.3%) | 2,233 (37.0%) | 183 (16.9%) | 198 (14.0%) | 128 (28.5%) | 3 (15.8%) | ||
| Middle | 30 (31.9%) | 2,021 (33.5%) | 249 (23.0%) | 262 (18.5%) | 127 (28.3%) | 8 (42.1%) | ||
| Low | 28 (29.8%) | 1,781 (29.5%) | 653 (60.2%) | 955 (67.5%) | 194 (43.2%) | 8 (42.1%) | ||
| Pre (<50 yr) | 25 (26.6%) | 1,565 (25.9%) | 389 (35.9%) | 648 (45.8%) | 162 (36.1%) | 8 (42.1%) | ||
| Post (≥50 yr) | 69 (73.4%) | 4,470 (74.1%) | 696 (64.1%) | 767 (54.2%) | 287 (63.9%) | 11 (57.9%) | ||
| 18.6 (15) | 17.7 (13) | 29.4 (18) | 35.2 (21) | 23.7 (17) | 28.8 (18) | |||
| 58.5 (11.7) | 60.1 (14.6) | 56.2 (14.5) | 52.6 (14) | 54.0 (12.5) | 54.8 (12.7) | |||
| 50.5 (51.3) | 47.6 (49.3) | 33.2 (37.5) | 43.1 (44.2) | 49.7 (47.4) | 24.8 (25.7) | |||
aNHW=Non-Hispanic White.
bNHB = Non-Hispanic Black.
cAI_Al = American Indian/Alaskan native.
d Sample size for ER and PR for cases diagnosed 1990–2008 only (NHW=5650, NHB=1036, Hispanic=1349, Arab=90, Asian=425, AI_Al=19).
Combined hormonal status based only on non-missing data from 1990–2008 (sample size for NHW = 3935, NHB=702, Hispanic =942 , Arab=73, Asian=306, Al_AI=14).
Sample size for HER2 for cases diagnosed 1999–2008 (NHW=1209, NHB=524, Hispanic=830, Arab=48, Asian=267, Al_AI=11).
% No Education (25 years of age or older without a high school diploma) and Education (tertiles of distribution) based on census tract-level information.
*ANOVA test for continuous variables, chi-sq for categorical (or Fisher's exact test for cell counts <5), log-rank test for Survival.
Proportion of IBC out of all breast cancers by race and registry
| Race | All Breast Cancer | IBC | %IBC | p-value |
|---|---|---|---|---|
| All Races combined | 621,465 | 9,135 | 1.47% | - |
| NHW | 462,717 | 6,035 | 1.30% | |
| NHB | 49,980 | 1,085 | 2.17% | |
| Hispanic | 61,062 | 1,415 | 2.32% | |
| Arab-American | 5,539 | 94 | 1.70% | |
| Asian | 37,085 | 449 | 1.21% | |
| American Indian/Alaskan | 652 | 19 | 2.91% | |
| Other | 506 | 6 | 1.19% | |
| Unknown | 3,924 | 32 | 0.82% | |
| New Jersey Registry | 135,764 | 1,333 | 0.98% | |
| Detroit Registry | 60,412 | 808 | 1.34% | |
| California Registry | 425,289 | 6,994 | 1.64% |
*P-value from chi square test.
Odds ratios (95% CI) for IBC by race
| Race | Crude Model | Age-Adjusted | HLMa |
|---|---|---|---|
| Non-Hispanic White | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| Non-Hispanic Black | 1.8 (1.7, 2.0) | 1.7 (1.6, 1.8) | 1.3 (1.2, 1.4) |
| Hispanic | 1.7 (1.6, 1.8) | 1.5 (1.4, 1.6) | 1.2 (1.1, 1.3) |
| Arab-American | 1.4 (1.1, 1.8) | 1.3 (1.1, 1.6) | 1.5 (1.2, 1.9) |
| Asian | 0.9 (0.8, 0.9) | 0.8 (0.7, 0.8) | 0.6 (0.6, 0.7) |
| American Indian/Alaskan | 2.2 (1.4, 3.5) | 2.0 (1.2, 3.2) | 1.9 (1.1, 3.4) |
| Other | 0.9 (0.3, 2.3) | 0.8 (0.3, 2.0) | 1.1 (0.3, 3.8) |
| Unknown | 0.6 (0.4, 0.9) | 0.6 (0.4, 0.9) | 0.9 (0.6, 1.3) |
a=Hierarchical logistic regression model adjusted for age, ER, PR, Her2, registry and census tract-level education and included interaction term between race and ER.
Odds ratios (95% CI) for marker status at IBC diagnosis by race
| Markera | NHW | NHB | Hispanic | Arab | Asian | AI_Al |
|---|---|---|---|---|---|---|
| ER+PR+ | 1.0 | 0.75 (0.46, 1.2) | 0.88 (0.7, 1.1) | 0.74 (0.25, 2.2) | ||
| ER- PR- | 1.0 | 1.45 (0.9, 2.2) | 1.56 (0.6, 4.0) |
a ER and PR non-missing data from 1990–2008 only (sample size for NHW = 3935, NHB=702, Hispanic =942 , Arab=73, Asian=306, Al_AI=14).
Study population characteristics of IBC cases by menopausal status (age <50 yr vs. >=50 yr)
| All IBC | Premenopausal IBC | Postmenopausal IBC | p-value | |||||
|---|---|---|---|---|---|---|---|---|
| (n=9,135) | (n=2811) | (n=6,324) | ||||||
| n | (%) | n | (%) | n | (%) | |||
| Non-Hispanic White | 6,035 | (66.1%) | 1,565 | (25.9%) | 4,470 | (74.1%) | ||
| Non-Hispanic Black | 1,085 | (11.9%) | 389 | (35.9%) | 696 | (64.1%) | ||
| Arab-American | 94 | (1%) | 25 | (26.6%) | 69 | (73.4%) | ||
| Hispanic | 1,415 | (15.5%) | 648 | (45.8%) | 767 | |||
| Asian | 449 | (4.9%) | 162 | (36.1%) | 287 | (63.9%) | ||
| American Indian/Alaskan | 19 | (0.2%) | 8 | (42.1%) | 11 | (57.9%) | ||
| Other | 6 | (0.07%) | 1 | (16.7%) | 5 | (83.3%) | ||
| Unknown | 32 | (0.35%) | 13 | (40.6%) | 19 | (59.4%) | ||
| Positive | 3,258 | (37.9%) | 893 | (33.8%) | 2,365 | (39.7%) | ||
| Negative | 2,909 | (33.8%) | 1,017 | (38.4%) | 1,892 | (31.7%) | ||
| Unknown | 2,438 | (28.3%) | 735 | (27.8%) | 1,703 | (28.6%) | ||
| Positive | 2,551 | (29.7%) | 768 | (29.0%) | 1,783 | (29.9%) | ||
| Negative | 3,480 | (40.4%) | 1,109 | (41.9%) | 2,371 | (39.8%) | ||
| Unknown | 2,574 | (29.9%) | 768 | (29.0%) | 1,806 | (30.3%) | ||
| Positive | 1,042 | (23.6%) | 349 | (27.3%) | 693 | (22.1%) | ||
| Negative | 1,496 | (33.9%) | 426 | (33.4%) | 1,070 | (34.1%) | ||
| Unknown | 1,879 | (42.5%) | 502 | (39.3%) | 1,377 | (43.8%) | ||
| High | 2,801 | (30.7%) | 814 | (29.0%) | 1,987 | (31.4%) | ||
| Middle | 2,702 | (29.6%) | 756 | (26.9%) | 1,946 | (30.8%) | ||
| Low | 3,632 | (39.8%) | 1,241 | (44.2%) | 2,391 | (37.8%) | ||
| 22.1 | (17) | 24.1 | (18.4) | 21.2 | (16.3) | |||
| 58.1 | (14.7) | 41.7 | (5.8) | 65.4 | (11.2) | |||
| 46.5 | (122.2) | 96.4 | (77.3) | 59.2 | (61.1) | |||
a Sample size for ER and PR for cases diagnosed 1990–2008 only (IBC=8,605, pre-menopause=2,645, post-menopause =5,960)).
Sample size for HER2 for cases diagnosed 1999–2008 (IBC=4,417, pre-menopause=1,277, post-menopause =3,140).
% No Education (25 years of age or older without a high school diploma) and Education (tertiles of distribution) based on census tract-level information.
* ANOVA test for continuous variables, chi-sq for categorical (or Fisher's exact test for cell counts <5), log-rank test for Survival. All statistical tests comparing differences in premenopausal and postmenopausal IBC cases.